No Detail Found!

Significance of CA15-3 in carcinoma of the breast with visceral metastases

Author(s)
Bhunisha Department of Medical Oncology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Ghulam Haider Department of Medical Oncology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Zoya Shaikh Department of Medical Oncology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Paras Memon Department of Medical Oncology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Aisha Shahid Department of Medical Oncology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Raja Rahul Department of Medical Oncology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Pavan Kumar Department of Anaesthesiology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Shumyla Beg Department of Medical Oncology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Jai Parkash Department of Medical Oncology, Jinnah Post Graduate and Medical Centre, Karachi-Pakistan
Abstract
Background: The most common malignancy and second most common cause of death is breast cancer among women. About 2.09 million fatalities from breast cancer happened in 2018. The objective was to evaluate the elevated CA15-3 in breast cancer patients with visceral metastases presenting at the tertiary care hospital of Karachi. Methods: It was a cross-sectional study conducted at the Department of Oncology of Jinnah Postgraduate Medical Center from 15th December 2018 to 15th November 2019. Female patients aged 26-80 years diagnosed with visceral metastatic (defined as metastasis to lung, liver, brain and adrenal glands) breast cancer were included in the study. The diagnosis of breast cancer was confirmed on histopathology whereas the metastatic sites were evaluated using physical examination and imaging. The serum CA15-3 concentration was assessed using assay kits. The serum CA15-3 level of 0-32 U/ml was taken as normal range for all the patients whereas CA15-3 level greater than 32 U/L was considered as elevated CA15-3. SPSS version 23 was used to enter and analyze data. Results: A total of 139 females were included in the study. The mean age & BMI of the patients were reported as 46.5 years & 26.69 kg/m2. In the majority of the patients' metastases were detected in the liver (n=54), 92 in the lungs+ parenchymal disease, 20 in adrenal glands, 12 in pleural effusion and 10 in the brain. Out of 139 patients with visceral metastases, 52(37.4%) had normal CA15-3 level whereas 87 (62.6%) had elevated serum CA15-3 levels (>32 U/L). Conclusion: The serum CA15-3 tumour marker is elevated significantly in visceral metastases and can be used as a prognostic marker in metastatic breast cancer patients.
Publication Details
Page(s) 710-714
Published Journal: Journal of Ayub Medical College, Volume: 35, Issue: 4(S), Year: 2023

Request the full text from PASTIC

Keywords
invasive ductal carcinoma, Metastases, Metastatic Breast Cancer, Tumour marker, Elevated CA15-3, Visceral metastases
References
WHO. Cancer .2018 .. , : .
.2019 .. U.S. Breast Cancer Statistics, 2 : .
Sultana S,Akhtar N,Rehman JU,Rehman RU . .. [cited 2019 July, 20 : .
Prevalence .2014 .risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev, 15(11) : 4411-6.
Cancer Cancer.net. Breast .2015 .Management of patients with hormone receptorpositive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res, 7 : 37-46.
DA Yardley .2010 .Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer, 10(1) : 64-73.
Imamura M,Morimoto T,Nomura T,Michishita S,Nishimukai A,Higuchi T . .independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. , : .
.2018 .. World J Surg Oncol, 16(1) : 26.
Bahrami-Ahmadi A,Makarian F,Mortazavizadeh MR,Yazdi MF,Chamani M. .2012 .Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients. J Res Med Sci, 17(9) : 850-4.
Dong Y,Hou H,Wang C,Li J,Yao Q,Amer S .2015 .The Diagnostic Value of 18F-FDG PET/CT in Association with Serum Tumor Marker Assays in Breast Cancer Recurrence and Metastasis. Biomed Res Int, : 489021.
Laessig D,Nagel D,Heinemann V,Untch M,Kahlert S,Bauerfeind I .2007 .Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res, 27(4A) : 1963-8.
Cronin-Fenton D,Kjaersgaard A,Norgaard M,Amelio J,Liede A,Hernandez RK .2018 .Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Res Treat, 167(2) : 517-28.
Fejzic H,Mujagic S,Azabagic S,Burina M. .2015 .Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad, 44(1) : 39-46.
Ghoncheh M,Pournamdar Z,Salehiniya H .2016 .Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev, 17(S3) : 43-6.
Berruti A,Tampellini M,Torta M,Buniva T,Gorzegno G,Dogliotti L .1994 .Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer, 30a(14) : 2082-4.
Taghizadeh A,Pourali L,Joudi M,Salehi M,Eshghi S,Torabian F .2019 .Assessment of Elevated Serum Tumor Markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA15-3) among Patients with Different Subtypes of Metastatic Breast Cancer. Middle East J Cancer, 10(1) : 17-22.
Ali HQ,Mahdi NK,Al-Jowher MH .2013 .The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer. J Pak Med Assoc, 63(9) : 1138-41.
Nieder C,Dalhaug A,Haukland E,Mannsaker B,Pawinski A .2017 .Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. J Clin Med Res, 9(3) : 183-7.
Fatima H,Maqbool A,Siddiqui M,Haider G,Sohail H,Saleem O .2016 .Significance of Tumor Marker CA15-3 in Metastatic Breast Cancer. J Cancer Tumor Int, 4(3) : 1-12.
Shao Y,Sun X,He Y,Liu C,Liu H. Elevated C .2015 .Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLoS One, 10(7) : e0133830.
Osman AM,Hamid ME,Satti AH,Goreish IA .2016 .High Concentration of Tumor Marker Cancer Antigen CA15-3 in Breast CancerPatients after Surgery. Breast Cancer Curr Res, 1(114) : 2.
Darlix A,Lamy PJ,Lopez-Crapez E,Braccini AL,Firmin N,Romieu G .2016 .Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer, 16 : 428.
Hosseini SM,Razmjoo S,Arvandi SH,Barat T. CEA .2015 .3 Serum Level in Metastatic Breast Cancer and its Correlation with Distant Metastasis. Age, 500(40) : 37.
0

Citations

0

Downloads

31

Views